ImmunityBio (IBRX) AI Stock Analysis

• Market Cap: $2.03B
• Dividend Yield: N/A
• Average Volume (3M): 9.24M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.32
• Revenue Growth: 1025.95%
• EPS Growth: 52.91%
• Country: US
• Employees: 671
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.07
• Shares Outstanding: 945,254,700
• 10 Day Avg. Volume: 9,515,214
• 30 Day Avg. Volume: 9,243,007
• PEG Ratio: 0.09
• Price to Book (P/B): -3.66
• Price to Sales (P/S): 121.07
• P/FCF Ratio: -4.48
• Enterprise Value/Market Cap: 1.44
• Enterprise Value/Revenue: 35.53
• Enterprise Value/Gross Profit: 37.49
• Enterprise Value/Ebitda: -12.61
• 1Y Price Target: $7.00
• Price Target Upside: 228.64% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -0.49
• Revenue Forecast (FY): $110.16M

• Rating: 41 Neutral
• Price Target: $2.00 ▼(-6.10% Downside)

ImmunityBio's overall stock score is primarily impacted by its financial performance, which is weak due to significant profitability and financial stability challenges. The technical analysis also indicates a bearish trend, further weighing down the score. Valuation metrics are poor, with a negative P/E ratio and no dividend yield, reflecting the company's financial struggles.

Positive Factors

Revenue Growth

Strong revenue growth indicates increasing demand for ImmunityBio's products, suggesting successful market penetration and potential for future expansion.

Product Adoption

The rapid adoption of ANKTIVA highlights its effectiveness and acceptance in the market, which could lead to sustained revenue growth and market leadership in its therapeutic area.

Strategic Partnerships

Being selected as a preferred drug by a major organization enhances ImmunityBio's market credibility and can drive significant sales volume, supporting long-term growth.

Negative Factors

Financial Stability

Negative equity suggests financial instability, which may limit the company's ability to invest in growth opportunities and sustain operations without external funding.

Profitability Challenges

Ongoing profitability challenges could hinder ImmunityBio's ability to reinvest in R&D and expand its product pipeline, affecting long-term competitiveness.

Cash Flow Issues

Negative cash flows indicate potential liquidity issues, which may constrain ImmunityBio's operational flexibility and ability to fund strategic initiatives.

ImmunityBio Business Overview & Revenue Model

Company Description

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.

How the Company Makes Money

ImmunityBio generates revenue primarily through the development and commercialization of its therapeutic products, which includes potential licensing agreements and collaborations with other pharmaceutical companies. Key revenue streams include milestone payments from partnerships, government grants for research and development, and the eventual sale of approved therapies. The company may also engage in public and private equity financing to support its research initiatives. Significant partnerships with larger biopharmaceutical companies may also contribute to its earnings, particularly if those collaborations lead to successful product development and commercialization.

ImmunityBio Financial Statement Overview

Summary

ImmunityBio is experiencing strong revenue growth but faces significant profitability and financial stability challenges. The negative equity and high leverage are concerning, and cash flow issues persist despite some improvement in free cash flow growth. The company needs to address these challenges to improve its financial health.

Income Statement

ImmunityBio shows significant revenue growth in the TTM period, with a 45.86% increase. However, the company is struggling with profitability, as indicated by negative net profit margins and EBIT margins. The gross profit margin is high, but the net income remains negative, reflecting ongoing operational challenges.

Balance Sheet

The balance sheet reveals a negative stockholders' equity, indicating financial instability. The debt-to-equity ratio is negative due to negative equity, and the return on equity is also negative, reflecting poor financial health and high leverage.

Cash Flow

Cash flow analysis shows negative operating and free cash flows, with a slight improvement in free cash flow growth. The company has a high free cash flow to net income ratio, but the negative operating cash flow coverage ratio indicates cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	82.56M	14.74M	622.00K	240.00K	934.00K	605.00K
Gross Profit	78.23M	14.74M	622.00K	240.00K	934.00K	-8.54M
EBITDA	-232.64M	-264.43M	-478.66M	-351.88M	-320.75M	-187.93M
Net Income	-348.62M	-413.56M	-583.20M	-416.57M	-346.79M	-224.19M
Balance Sheet
Total Assets	0.00	382.93M	504.45M	362.36M	468.91M	221.38M
Cash, Cash Equivalents and Short-Term Investments	153.66M	149.81M	266.46M	107.18M	317.12M	96.06M
Total Debt	0.00	504.17M	726.72M	723.77M	645.66M	275.55M
Total Liabilities	569.82M	871.06M	1.09B	812.18M	712.82M	339.87M
Stockholders Equity	-569.82M	-489.10M	-586.99M	-447.33M	-242.17M	-119.81M
Cash Flow
Free Cash Flow	-324.01M	-398.12M	-397.34M	-415.67M	-307.98M	-173.39M
Operating Cash Flow	-319.70M	-391.24M	-366.76M	-337.51M	-274.42M	-171.72M
Investing Cash Flow	-183.54M	-12.25M	-30.47M	27.30M	-84.89M	-19.81M
Financing Cash Flow	452.28M	281.63M	558.34M	233.61M	505.44M	150.68M

ImmunityBio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.13
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IBRX, the sentiment is Negative. The current price of 2.13 is below the 20-day moving average (MA) of 2.39, below the 50-day MA of 2.48, and below the 200-day MA of 2.71, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 37.33 is Neutral, neither overbought nor oversold. The STOCH value of 14.28 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IBRX.

ImmunityBio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CPRX	83 Outperform	$2.62B	12.25	27.52%	―	25.56%	44.42%
ARQT	59 Neutral	$2.99B	―	-28.17%	―	129.21%	80.35%
IMCR	52 Neutral	$1.55B	―	-5.38%	―	26.90%	62.72%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IMVT	45 Neutral	$4.11B	―	-77.58%	―	―	-48.38%
IBRX	41 Neutral	$2.03B	―	―	―	1025.95%	52.91%
BEAM	40 Neutral	$2.35B	-5.01	-47.19%	―	-84.07%	-157.71%

ImmunityBio Corporate Events

ImmunityBio’s Anktiva: A Promising Treatment for Long COVID?

Study Overview: ImmunityBio Inc. is conducting a clinical study titled ‘Single Arm Study to Evaluate the Safety of Nogapendekin Alfa Inbakicept (NAI) in Participants With Long COVID.’ The study aims to assess the safety and effectiveness of Anktiva in treating Long COVID, a condition characterized by persistent symptoms following a COVID-19 infection. This research is significant as it addresses the growing need for effective treatments for Long COVID, which affects a substantial number of individuals post-infection.

ImmunityBio’s Innovative Phase 2 Lymphoma Study: A Potential Game-Changer?

ImmunityBio Inc. is conducting an open-label, Phase 2 study titled ‘Open Label, Phase 2 Study of CD19t-haNK and N-803 in Combination With Rituximab in Participants With Relapsed/ Refractory B-cell Non-Hodgkin Lymphoma.’ The study aims to evaluate the efficacy of a combination therapy involving CD19t-haNK and N-803 with Rituximab in treating relapsed or refractory B-cell Non-Hodgkin Lymphoma. This research is significant as it explores novel immunotherapy approaches for challenging lymphoma cases.

ImmunityBio’s Anktiva Study: A Potential Breakthrough for Long COVID Treatment

ImmunityBio Inc. is conducting a study titled ‘Single Arm Study to Evaluate the Safety of Nogapendekin Alfa Inbakicept (NAI) in Participants With Long COVID.’ The study aims to assess the safety and effectiveness of Anktiva in treating Long COVID, characterized by persistent symptoms post-COVID-19 infection. This research is significant as it addresses ongoing health challenges faced by COVID-19 survivors.

ImmunityBio’s Shareholder Settlement Gains Preliminary Approval

On July 29, 2025, the United States District Court for the Southern District of California preliminarily approved a proposed settlement of shareholder derivative actions against ImmunityBio‘s individual defendants. The settlement includes corporate governance reforms and attorneys’ fees covered by insurance, with a final approval hearing set for November 4, 2025. The derivative actions alleged breaches of fiduciary duties and misleading statements by ImmunityBio’s officers regarding manufacturing practices, impacting the company’s stock price and leading to a related securities fraud class action.

The most recent analyst rating on (IBRX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on ImmunityBio stock, see the IBRX Stock Forecast page.

ImmunityBio Reports Revenue Growth Amidst Continued Investments

ImmunityBio, Inc. is a biotechnology company focused on developing next-generation therapies to enhance the immune system’s ability to fight cancers and infectious diseases. The company operates in the healthcare sector, with a unique approach that integrates immunotherapy and cell therapy platforms.